Effects of combination therapy with interferon and ofloxacin on chronic type C hepatitis: A pilot study

Journal of Gastroenterology and Hepatology (Australia)

Volumn 11, Issue 11, 1996, Pages 1006-1011

  Tsutsumi, Mikihiro ^a   Takada, Akira ^a   Takase, Shujiro ^a   Sawada, Makoto ^a  

^a KANAZAWA MEDICAL UNIVERSITY   (Japan)

Author keywords

Combination therapy; Hepatitis C; Interferon; Ofloxacin; Pilot study

Indexed keywords

ALPHA INTERFERON; AMINOTRANSFERASE; INTERFERON; OFLOXACIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HEPATITIS C; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; MALE; PRIORITY JOURNAL;

EID: 0029952886     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1746.1996.tb00022.x     Document Type: Article

References (20)

1. Marcellin P, Boyer N, Giostra E et al. Recombinant human alpha-interferon in patients with chronic non-A, non-B hepatitis: A multicenter randomized controlled trial from France. Hepatology 1991; 13: 393-7.
2. Hagiwara H, Hayashi N, Mita E et al. Quantitative analysis of hepatitis C virus RNA in serum during interferon-alpha therapy. Gastroenterology 1993; 104: 877-83.
3. Takase S, Takada N, Sawada M et al. Effects of interferon treatment for chronic type C liver disease: A co-operative study in three hospitals. Int. Hepatol. Commun. 1993; 1: 321-25.
4. Yoshioka K, Kakumu S, Wakita T et al. Detection of hepatitis C virus by polymerase chain reaction and response to interferon-therapy: Relationship to genotypes of hepatitis C virus. Hepatology 1992; 16: 293-9.
5. Mita E, Hayashi N, Hagiwara H et al. Predicting interferon therapy efficacy from hepatitis C virus genotype and RNA titer. Dig. Dis. Sci. 1994; 39: 977-82.
6. Enomoto N, Sato C, Kurosaki M, Marumo F. Hepatitis C virus after interferon treatment has the variation in the hypervariable region of envelope 2 gene. J. Hepatol. 1994; 20: 252-61.
7. Enomoto N, Sakuma I, Asahina Y et al. Comparison of full-length sequences of interferon sensitive and resistant hepatitis C virus 1b: Sensitivity of interferon is conferred by aminoacid substitutions in the NS5A region. J. Clin. Invest. 1995; 96: 224-30.
8. Ikeda S, Yazawa M, Nishimura C. Antiviral activity and inhibition of topoisomerase by ofloxacin, a new quinolone derivative. Antiviral Res. 1987; 8: 103-13.
9. Nozaki-Renard J, Iino T, Sato Y, Marumoto Y, Ohta G, Furusawa M. Fluorquinolones protect human lymphocyte CEM cell line from HIV-1-induced cytotoxicity. Cell Struct. Function 1990; 15: 295-9.
10. Takada A, Takase S, Tsutsumi M, Sawada M. Effects of ofloxacin for type C hepatitis. Int. Hepatol. Commun. 1993; 1: 272-7.
11. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: Diagnosis, grading and staging. Hepatology 1994; 19: 1513-20.
12. Mimms L, Vallari D, Ducharme L, Holland P, Kuramoto IK, Zeldis J. Specificity of anti-HCV ELISA assessed by reaction to three immunodominant HCV regions. Lancet 1990; 336: 1590-1.
13. Okamoto H, Okada S, Sugiyama Y et al. Detection of hepatitis C virus RNA by a two stage polymerase chain reaction with two primers deduced from the 5′-non-coding region. Jpn. J. Exp. Med. 1990; 60: 215-22.
14. Enomoto N, Takada A, Nakao T, Date T. There are two major types of chronic hepatitis C virus in Japan. Biochem. Biophys. Res. Commun. 1990; 170: 1021-5.
15. Okamoto H, Sugiyama Y, Okada S et al. Typing hepatitis C virus by polymerase chain reaction with type-specific primers: Application to clinical surveys and tracing infectious sources. J. Gen. Virol. 1992; 73: 673-9.
16. Ishiyama N, Katayama K, Ishimi N et al. Quantitative detection of hepatitis C virus RNA by multicyclic RT-PCR. Int. Hepatol. Commun. 1993; 1: 72-9.
17. Iino S. Interferon therapy in hepatitis C-refractory hepatitis. Report of the research subgroup of treatment of chronic hepatitis. Gastroenterol. Jpn. 1993; 28 (Suppl. 4): 139-42.
18. Sumiyoshi Y, Nishikawa T, Watanabe T, Kano K. Inhibition of retrovirus RNA-dependent DNA polymerase by novobiocin and nalidixic acid. J. Gen. Virol. 1983; 640: 2329-33.
19. DiBisheglie AM, Shindo M, Fong T-L et al. A pilot study of rivavirin therapy for chronic hepatitis C. Hepatology 1992; 16: 649-54.
20. Takada A, Takase S, Sawada M, Tsutsumi M. Effects of azidithymidine on type C hepatitis. Int. Hepatol. Commun. 1993; 1: 209-14.